1 active not recruiting, 1 not yet recruiting. 2 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 2 | Active not recruiting 1, Not yet recruiting 1 |
Follow defactinib: new trials by email Literature Review of defactinib trials Research Report on defactinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas avutometinib and defactinib for 3 weeks on/1 week off, MGMT-unmethylated GBM with Radiation - MGMT-unmethylated Glioblastoma (GBM), IDH Wildtype Glioblastoma | Early Phase 1 | Not yet recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 22 | 2026-11-10 | 2026-08-26 |
| Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma Avutometinib, Biospecimen Collection, Defactinib - Glioblastoma, Recurrent Glioblastoma | Early Phase 1 | Active not recruiting | Emory University | 14 | 2023-07-28 | 2025-12-15 |
Glioblastoma (2)
Emory University (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (2) · Puerto Rico (1)
Karisa C Schreck, MD, PhD (1) · Kimberly B. Hoang, MD (1)
P30CA138292 (1)